secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001558370-25-007497
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD
--------------------------------------------------------------------------------

- Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.
- Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.
- FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.
- AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.
- Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/0001558370-25-007497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/mgtx-20250513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer